C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  S T A TI S TI C A L A N A L Y SI S  P L A N  
Pr ot oc ol  N u m ber : M E DI -M M 3 6 -2 0 6   
  
St u d y Title:  A P hase 2 M ulti -ce nter, O p e n -la bel St u d y t o Assess P har m ac o ki netic 
Para meters a n d Safet y of T o pical M M 3 6 ( 1 %) i n Pe diatric S u bjects 2 t o < 1 8 Years of A ge 
wit h At o pic Der matitis U n der Ma xi mal Use C o n diti o ns   
  
De vel o p me nt P hase of St u d y : 2  
  
S p o ns or:  Me di metri ks P har mace uticals, I nc.   
S p o ns or C o ntact:    
  
Statistical A nal ysis Pla n base d o n Pr ot oc ol Versi o n : A me n de d Pr ot oc ol 1 2 0  J a n uar y  2 0 1 7  
  
Statistical A nal ysis Pla n Date:  Ma y 1 8, 2 0 1 7   
Statistical A nal ysis Pla n Versi o n : Draft v 1  P er s o n al D at a 
  
P er s o n al D at a 
P er s o n al D at a 
P er s o n al D at a 
CONFIDENTIAL  
   
Statistical Analysis Plan  for Medimetriks Pharmaceuticals, Inc.  Page 3 
Protocol Number: MEDI -MM36 -206 May 18, 2017  TABLE OF CONTENTS  
1. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ....................................5  
2. INTRODUCTION .................................................................................................................6  
3. STUDY OBJECTIVES  .........................................................................................................6  
3.1 Primary Objective  ...........................................................................................................6  
3.2 Secondary Objectives  .....................................................................................................7  
3.3 Exploratory Objectives ...................................................................................................7  
4. STUDY DESIGN ...................................................................................................................7  
4.1 Overall Study Design  ......................................................................................................7  
4.1.1  Schedule of Visits and Assessments .................................................................8  
4.1.2  Method of Assigning Subjects to Treatment Groups ........................................8  
4.1.3  Blinding .............................................................................................................8  
4.2 Determinat ion of Sample Size ........................................................................................8  
5. CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES  .........9  
6. PHARMACOKINETIC, EFFICACY AND SAFETY END POINTS  ..............................9  
6.1 Pharmacokinetic Endpoints ............................................................................................9  
6.1.1  Primary Pharmacokinetic Endpoint ...................................................................9  
6.2 Efficacy Endpoints ..........................................................................................................9  
6.2.1  Primary Efficacy Endpoints ..............................................................................9  
6.2.2  Secondary Efficacy Endpoints ..........................................................................9  
6.2.3  Additional Efficacy Endpoints ..........................................................................9  
6.3 Safety Endpoints  ...........................................................................................................11  
6.3.1  Primary Safety Endpoint .................................................................................11  
6.3.2  Secondary Safety Endpoints ............................................................................11  
7. STATISTICAL METHODS AND ANALYSIS  ................................................................12  
7.1 General Methodology ...................................................................................................12  
7.2 Adjustments for Covariates ..........................................................................................12  
7.3 Handling of Dropouts or Missing Data .........................................................................12  
7.4 Interim Analyses and Data Monitoring ........................................................................12  
7.5 Multicenter Studies  .......................................................................................................13  
7.6 Multiple Comparisons/Multiplicity  ..............................................................................13  
7.7 Examination of Subgroups ............................................................................................13  
7.8 Analysis Populations .....................................................................................................13  
7.8.1  Intent- to-Treat (ITT) Population .....................................................................13  
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 4 
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  7. 8. 2  Safet y P o p ulati o n ............................................................................................ 1 3  
7. 9  Statistical A nal ysis  ........................................................................................................ 1 3  
7. 9. 1  Baseli ne Defi niti o n  .......................................................................................... 1 3  
7. 9. 2  Visit Wi n d o wi n g  ............................................................................................. 1 4  
7. 9. 3  S u bject Dis p ositi o n  .......................................................................................... 1 4  
7. 9. 4  Pr ot oc ol De viati o ns ......................................................................................... 1 5  
7. 9. 5  De m o gra p hic a n d Baseli ne C haracteristics  ..................................................... 1 5  
7. 9. 6  Pri or a n d C o nc o mita nt Me dicati o ns ................................................................ 1 5  
7. 9. 7  P har mac o ki netic A n al ys es ............................................................................... 1 5  
7. 9. 8  Efficac y A nal yses  ............................................................................................ 1 6  
7. 9. 8. 1  Pri mar y Efficac y A nal ysis  ........................................................... 1 6  
7. 9. 8. 2  Sec o n dar y Efficac y A nal ysis  ....................................................... 1 6  
7. 9. 8. 3  E x pl orat or y Effi cac y A n al yses  .................................................... 1 7  
  
  
  
  
  
  
  
7. 9. 9  Sa fet y A nal yses  ............................................................................................... 2 0  
7. 9. 9. 1  E xte nt of E x p os ure ....................................................................... 2 0  
7. 9. 9. 2  A d verse E v e nts  ............................................................................ 2 0  
7. 9. 9. 3  Cli nical La b or at or y E val uti o ns .................................................... 2 1  
7. 9. 9. 4  Ot her O bser vati o ns Relate d t o Safet y  .......................................... 2 1  
7. 9. 9. 4. 1  E C G Meas ure m e nts  .............................................. 2 1  
7. 9. 9. 4. 2  Vital Si g ns  ............................................................ 2 1  
7. 9. 9. 4. 3  P h ysical E x a mi nati o n  ........................................... 2 2  
8.  R E F E R E N C E S  .................................................................................................................... 2 2  C or p or at e C o nfi d e nti al I nf or m ati o n 
 
 
CONFIDENTIAL  
   
Statistical Analysis Plan  for Medimetriks Pharmaceuticals, Inc.  Page 5 
Protocol Number: MEDI -MM36 -206 May 18, 2017  1. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
AD Atopic dermatitis  
AE(s)  Adverse event(s) 
ATC  Anatomical therapeutic chemical  
AUC (0-last) Area under the plasma concentration -time curve from time zero to the time 
of last quantifiable plasma concentration 
BLQ  Below the limit of quanti tation  
BSA  Body surface area  
Cmax Maximum plasma  concentration 
CV Coefficient of variation  
DSMB  Data Safety Monitoring Board  
  
ECG  Elec
trocardiogram  
GM Geometric mean  
  
ITT Intent -to-treat 
MedDRA  M edical Dictionary for R egulatory Activities  
Max Maximum  
Min Minimum  
n Number  of observations  
nquant Number of quantifiable concentrations 
N Number of subjects (sample size) 
  
PDE  Phosphodiesterase 
PK Pharmacokinetic  
  
QTcB QT int
erval corrected for heart rate using Bazett’s formula  
QTcF QT interval corrected for heart rate using Fr iderici a’s formula  
SAE(s) S erious adverse event(s)  
SAS®  Statistical Analysis System (SAS® Institute Inc., Cary, NC)  
  
SD Standa
rd deviation  
TCIs Topical calcineurin inhibitors 
TEAE(s)  T reatment -emergent adverse event (s) 
Tmax Time of  maximum plasma concentration  

C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 6 
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7    
  
W H O -D D E W orl d Healt h Or ga nizati o n  Dr u g D icti o nar y  
2.  I N T R O D U C TI O N  
M M 3 6 (als o k n o w n as O P C- 2 7 1 a n d O P A- 1 5 4 0 6) is a n o vel n o nster oi dal p h os p h o diesterase t y pe 
4 ( P D E 4) i n hi bit or w hic h selecti vel y i n hi bits t he s y nt hesis of t he i ntr acell ul ar sec o n d m esse n gers 
t hat acti vate i nfla m mati o n.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.  S T U D Y O B J E C TI V E S  
3. 1  Pri m ar y O bjecti ve  
T he pri mar y o bjecti ve of t his st u d y is t o assess t he de gree of s yste mic e x p os ure (acti ve par e nt 
c o m p o u n d a n d meta b olites) f oll o wi n g 4 wee ks of t wice dail y d osi n g wit h M M 3 6 1 %, a p plie d 
t o picall y u n der ma xi mal - use c o n diti o ns; ≥ 3 5 % B o d y S urf ace Area [ B S A] i n v ol ve me nt 
(e x cl u di n g scal p a n d ve n o us access areas) i n s u bjects 2 t o less t ha n 1 2 years of a ge, a n d ≥ 2 5 % C or p or at e C o nfi d e nti al I nf or m ati o n 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 7 
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  (e x c l u di n g scal p a n d ve n o us access areas) i n s u bjects at least 1 2 years of a ge t o < 1 8 years of a ge 
wit h at o pic der matitis.  
3. 2  Sec o n d ar y O bjecti ves  
T he sec o n d ar y o bjecti ve of t his st u d y is t o assess t he safet y pr ofile of M M 3 6 1 % a p plie d 
t o picall y t wice dail y f o r u p t o 4 wee ks i n pe diatri c s u bjects 2 t o < 1 8 years of a ge, wit h at o pic 
der matitis.  
3. 3  E x pl or at or y O bjecti ves  
T his st u d y will als o e x pl ore t he I n v esti gat or - a n d s u bject -assesse d effi cac y pr ofile of M M 3 6 1 %, 
a p plie d t o picall y t wice d ail y f or u p t o 4 wee ks i n pe diatric s u bjects 2 t o < 1 8 years of a ge, wit h 
at o pic der matitis,  
 
 
 
. 
4.  S T U D Y D E SI G N  
4. 1  O ver all St u d y Desi g n C or p or at e C o nfi d e nti al I nf or m ati o n 
T his m ultice nter, o pe n- la bel st u d y, will e val uat e t he p har mac o ki netics, saf et y, t oler a bilit y, a n d 
t he e x pl orat or y efficac y of M M 3 6 1 % oi nt me nt w he n a p plie d t wice d ail y f or u p t o 4 wee ks i n 
s u bjects 2 t o < 1 8 years of a ge wit h at o pic d er matitis, at t he u p per ra n ge of disease se verit y. T his 
st u d y will als o e val uat e t he s yste mic a vaila bilit y of M M 3 6 1 % w he n a p plie d t o picall y u n der 
ma xi mal use c o n diti o ns.  
A p pr o xi matel y 4 5 s u bj ects will be re gistere d f or a n esti mate d 3 2 c o m plete d s u bjects. F oll o wi n g 
scree ni n g ( wit hi n 3 0 da ys pri or t o t he first d ose of st u d y dr u g) a n d c o nfir mati o n of st u d y 
q ualificati o n, s u bjects will be re gistere d a n d assi g ne d ( Da y 1) t o o ne of t hr ee gr o u ps bas e d o n t he 
s u bject’s a ge at Scree ni n g. T he first d ose of st u d y dr u g will be a p plie d i n t he st u d y cli nic ( Da y 1) 
a n d bl o o d sa m ples will be c ollecte d f or e v al uati o n of p har mac o ki netics ( P K ) pri or t o t he first 
a p plicati o n ( 0 h o urs) a n d at 1 h o ur ( ± 1 5 mi n utes), 4 h o urs ( ± 3 0 mi n utes) a n d at 8 h o urs ( ± 1 
h o ur) after a p plicati o n of st u d y dr u g. O n D a y 1 5, t he st u d y dr u g will a gai n be a p plie d i n t h e 
st u d y cli nic, a n d bl o o d sa m ples will be c ollecte d f or P K pri or t o d osi n g a n d at 1 h o ur ( ± 1 5 
mi n utes), 4 h o urs ( ± 3 0 mi n utes) a n d at 8 h o urs ( ± 1 h o ur) after a p plicati o n of st u d y dr u g. 
 
  
At Scree ni n g a n d Bas eli ne ( Da y 1) , s u bjects wit h at o pic der matitis t hat are 2 t o less t ha n 1 2 years 
of a ge ( Gr o u p 2 a n d 3) m ust ha ve a treata ble area c o m prisi n g ≥ 3 5 % B S A i n v ol ve me n t C or p or at e C o nfi d e nti al I nf or m ati o n 
CONFIDENTIAL  
   
Statistical Analysis Plan  for Medimetriks Pharmaceuticals, Inc.  Page 8 
Protocol Number: MEDI -MM36 -206 May 18, 2017  (excluding scalp and venous access areas), and subjects 12 years of age and older (Group 1) must 
have ≥ 25% BSA involvement (excluding scalp and venous access areas) (i.e., maximal use 
conditions). The same (or greater, BSA if area involved expands) amount of study drug topically 
applied at baseline will continue to be applied twice daily, to the same area where study drug was applied on Day 1, even if the % BSA improves over the course of the first 2 weeks (14 days) of 
treatment. Between Day 15 (after the maximal use application and collection of PK samples) and 
Day 28, the study drug will only be applied to the involved areas. The last application of study drug will be given the ev ening before the final visit (Day 29 ).  
The maximum individual study participation is approximate ly 60 days (screening (Day -30) 
through final Day 29 (± 1 day) Visit). 
4.1.1 Schedule of Visits and Assessments  
The schedule of assessments can be found in Section 1 of the protocol. 4.1.2 Method of Assigning Subjects to Treatment Groups  
This is  a non-randomized one-arm study with subjects split into three groups based on the 
subject’s age at Screening. Group 1 will consist of approximately 16 subjects who are 12 to < 18 
years  of age. Subjects in Group 1 must have ≥25% BSA involvement. Groups 2 and 3 will each 
contain approximately 8 subjects, and subjects must have ≥35% BSA involvement.  Group 2 will 
consist of subjects 6 to < 12 years of age and Group 3 will have subjects 2 to < 6  years of age. 
Following screening and confirmation of study qualification, subjects will be registered and 
assigned a kit of study drug. Five labeled tubes will be assembled into a subject box. Each box will be labeled with a single panel label and tamper sealed. Five labeled subject boxes will be 
assembled into block kits. Each kit will be labeled with a 2 -part te ar away label and tamper 
sealed. At Visit 2/Baseline, Visit 3/Week 1, Visit 4/Week 2 and Visit 5/Week 3, subjects will be 
dispensed tubes of study drug from the assigned kit. 
4.1.3 Blinding  
Not applicable.  
4.2 Determination of Sample Size  
The sample size is not driven by inferential statistics. A sample size of 32 subjects is set for  
qualitative investigation of the pharmacokinetic profile as well as the safety and tolerability and  
responsiveness (efficacy) of MM36 1% when applied topically twice daily for 4 weeks to 
pediatric subjects 2 to < 18 years of age. 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 9 
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  5.  C H A N G E S I N T H E C O N D U C T O F T H E S T U D Y O R P L A N N E D A N A L Y S E S  
T here are n o c ha n ges i n t he c o n d uct of t he st u d y or pla n ne d a n al ys es.  
6.  P H A R M A C O KI N E TI C, E F FI C A C Y  A N D S A F E T Y  E N D P OI N T S  
6. 1  P h ar m a c o ki netic E n d p oi nts  
6. 1. 1  Pri m ar y P h ar m a c o ki netic E n d p oi nt  
Deter mi nati o n of plas ma c o nce ntr ati o ns, of t he par e nt c o m p o u n d M M 3 6 a n d its meta b olites, 
after t he first t o pical a p pli cati o n of M M 3 6 a n d aft er t w o wee ks of t wice dail y a p plicati o n (stea d y 
state).  
6. 2  Effic ac y E n d p oi nts  
6. 2. 1  Pri m ar y Effic ac y E n d p oi nt s 
T here are n o pri mar y effi cac y e n d p oi nts.  
6. 2. 2  Sec o n d ar y Effic ac y E n d p oi nt s 
T here are n o s ec o n dar y efficac y e n d p oi nts. 
6. 2. 3  A d diti o n al Effic ac y E n d p oi nts  
T he e x pl orat or y effi cac y e n d p oi nts are as f oll o ws: 
  
 
 
 
  
 
 
 
  
 
 C or p or at e C o nfi d e nti al I nf or m ati o n 
 
 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 0  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7   
 
 
  
 
 
  
 
  
 
  
 
  
 
 
  
 
 
  
 
 
  
 
  
 
  
 
 
 
 C or p or at e C o nfi d e nti al I nf or m ati o n 
 
 
 
 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 1  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7    
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
  
 
 
6. 3  S af et y E n d p oi nts  
6. 3. 1  Pri m ar y S af et y E n d p oi nt 
T here are n o pri mar y saf et y e n d p oi nts.  
6. 3. 2  Sec o n d ar y S af et y E n d p oi nts 
T he sec o n d ar y saf et y  e n d p oi nts are as f oll o ws: 
• I n ci de nce a n d se v erit y of a p plicati o n site a d vers e e ve nts ( A Es);  
• I n ci de nce a n d se v erit y of all A Es a n d t heir r elati o ns hi p t o st u d y dr u g; 
• C or p or at e C o nfi d e nti al I nf or m ati o n 
I n ci de nce of cli nicall y m ea ni n gf ul c ha n ge fr o m b aseli ne i n safet y la b orat or y p ara m eters, 
1 2- lea d electr ocar di o gra ms ( E C G ), a n d vital si g ns; 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 2  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  • Pr o p orti o n of s u bjects w h o disc o nti n ue treat me nt d ue t o a n a d verse e v e nt. 
7.  S T A TI S TI C A L M E T H O D S  A N D AN A L Y SI S  
7. 1  Ge ner al Met h o d ol o g y 
All a nal ys es will be perf or me d b y  T he sta n d ar d o perati n g pr oce d ures of 
 will be f oll o we d i n t he creati o n a n d q ualit y c o ntr ol of all data dis pla ys a n d 
a nal ys es.  
Efficac y a nal ys es will be perf or me d f or t he i nte nt -t o -treat (I T T) p o p ulati o n a n d safet y a n d P K 
a nal ys es will be perf or m e d usi n g t he s afet y p o p ul ati o n.  
All a nal ys es will be perf or me d usi n g S A S ® Versi o n 9. 3 or later. C o nti n u o us data will be 
s u m marize d usi n g descri pti ve statistics ( n u m ber of val ues [ n], mea n, sta n dar d de viati o n [ S D], 
me dia n, mi ni m u m [ mi n], a n d ma xi m u m [ ma x]) . A d diti o nal s u m mar y statistics, c oeffi cie nt of 
variati o n ( C V %) a n d ge o metric mea n ( G M), will be i ncl u de d f or P K d ata s u m maries. P K 
c o nce ntr ati o n s u m maries will i ncl u de C V %, a n d P K para met er s u m maries will i ncl u de b ot h 
C V % a n d G M. Cate g ori cal data will be s u m marize d usi n g fre q u e nc y ta bles  (fre q u e ncies a n d 
perce nt s).  
Re p orte d A Es, me dical hist or y ter ms , a n d pri or a n d c o nc o mita nt pr oce d ures a n d t hera pies will 
be classifie d o n t he b asis of Me dical Dicti o nar y f or Re g ul at or y Acti vities ( Me d D R A) 
ter mi n ol o g y , Versi o n 1 9. 1. Pri or a n d c o nc o mita nt me dicati o ns a n d s ki n car e pr o d ucts will be 
classifie d o n t he basis of W orl d Healt h Or ga nizati o n Dr u g Dicti o nar y ( W H O- D D E) t er mi n ol o g y, 
F or mat B 2, Versi o n Mar c h 1, 2 0 1 6. 
Data c ollecte d at a ti me p oi nt  will be s u m marize d re gar dl ess of treat me nt wit h st u d y dr u g. P ost -
treat me nt assess me nts f or s u bjects w h o disc o nti n ue treat me nt b ut c o nti n ue d t o be f oll o we d i n t he 
st u d y will be i ncl u de d i n s u m maries.  
7. 2  A dj ust me nts f or C o v ari ates  
N ot a p plica ble t o t his st u d y.  
7. 3  H a n dli n g of Dr o p o uts or Missi n g D at a 
U nless ot her wise s pecifie d, m issi n g data will n ot be i m p ute d f or a n al ys es.    
7. 4  I nteri m A n al yses a n d D at a M o nit ori n g C o nfi d e nti al 
A n i n de pe n de nt D ata Saf et y M o nit ori n g B o ar d ( D S M B) will facilitate t he ma na ge me nt a n d 
i de ntificati o n of p ote ntial safet y c o n cer ns, o n a re g ular basis, t hat c o ul d affect t he safet y of trial 
s u bjects, a n d will e x a mi ne w het her t h e i nf or mati o n c ollecte d d uri n g t hes e peri o dic i nter vals is 
c o nsiste nt wit h k n o wle d ge a b o ut t he pr o d uct’s saf et y ( e. g., u na ntici pat e d a d verse e v e nts). T he C o nfi d e nti al 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 3  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  D S M B will als o assess w het her r e visi o ns t o t he st u d y pr ot o c ol a n d/ or c o ns e nt are re q uire d, a n d 
will e val uate t he o verall pr o gress of t he st u d y.  
T he D S M B will c o nsist of 3 v oti n g me m bers , a n d t he first D S M B data re vi e w meeti n g will be 
sc he d ule d after at least 5 0 % or 1 6 e nr olle d s u bjects i n t he st u d y. A d h oc m eeti n gs ma y b e 
re q ueste d b y a n y me m ber of t he D S M B or a n y ot her i n v ol ve d part y, if d ee me d necess ar y. 
F oll o wi n g eac h D S M B meeti n g ( pl a n ne d or a d h oc), t he D S M B will ma ke rec o m me n d ati o ns 
re gar di n g st u d y c o nti n uati o n, m o dificati o n or ter mi nati o n base d o n t he o bser ve d a d verse effects 
of t he treat me nt u n d er st u d y. D etails re gar di n g t h e p olicies a n d pr o ce d ur es of t he D S M B a n d 
i nter vals a n d data t o b e e val uate d will be descri be d i n t he D S M B C harter.  
A pre -s p ecifie d i nteri m a nal ysis will n ot be c o n d u cte d.  
7. 5  M ultice nter St u dies  
T he cli nical st u d y will be c o n d ucte d u n der a c o m m o n pr ot oc ol f or eac h i n vesti gati o nal site wit h 
t he i nte nti o n of p o oli n g t he data f or a nal ysis. E ver y eff ort will be ma d e t o pr o m ote c o nsiste nc y 
i n st u d y e x ec uti o n at eac h st u d y site.  
7. 6  M ulti ple C o m p aris o ns/ M ulti plicit y  
N o a dj ust me nts f or m ulti ple c o m paris o ns or m ulti plicit y will be ma de.  
7. 7  E x a mi n ati o n of S u b gr o u ps 
 a d verse e ve nts will  be s u m marize d b y 
a ge gr o u p (s u bj ects 2- 5 years ol d a n d s u bjects 6- 1 7 years ol d). 
7. 8  A n al ysis P o p ul ati o ns 
7. 8. 1  I nte nt -t o -Tre at (I T T) P o p ul ati o n  
All e nr olle d s u bjects w h o t o o k at least o ne d ose of st u d y dr u g will be i ncl u de d i n t he I T T 
p o p ulati o n .  All efficac y a na l ys es will be pre s e nte d usi n g t he I T T p o p ul ati o n. 
7. 8. 2  S af et y P o p ul ati o n 
All s u bjects i n t he I T T p o p ulati o n w h o ha ve at least o ne p ost- baseli ne safet y assess me nt will be 
i ncl u de d i n t he safet y p o p ulati o n. All safet y a nal yses will be perf or me d usi n g t he safet y 
p o p ulati o n. 
7. 9  St atistic al A n al ysis  
7. 9. 1  B aseli ne Defi niti o n  C or p or at e C o nfi d e nti al I nf or m ati o n 
Baseli ne is defi ne d as t he last n o n- missi n g assess me nt pri or t o first d ose of st u d y dr u g.   
CONFIDENTIAL  
   
Statistical Analysis Plan  for Medimetriks Pharmaceuticals, Inc.  Page 14 
Protocol Number: MEDI -MM36 -206 May 18, 2017  7.9.2 Visit Windowing  
Data will be summarized based on nominal visit indications with the exception of data captured 
at early termination  and unscheduled visits. Data from early termination and unscheduled visits 
will be summarized based on mapped visit values.  The analysis windows for early termination and unscheduled visits are presented in the following table. 
Analysi s Windows for Efficacy and Safety  Assessments  
Scheduled Visit  Target Study Day  Window (Days)  
Day 8 8 5 to 11 
Day 15  15 12 to 18 
Day 22  22 19 to 25 
Day 29  29 26 to 32 
Data collected at early termination and unscheduled visits prior to study day 5 will not be analyzed, with the exception of those identified as baseline values. Data collected at early 
termination and unscheduled visits after study day 32 will not be included in analyses. 
The definition for the study day included in each study window is defined as below:  Study Day Prior to Day 1 = Visit Date – Day 1 Date  
 Study Day On or After Day 1 = Visit Date – Day 1 Date + 1  
If an assessment’s mapped visit is a visit at which the subject has data present, or if no analyses 
are planned for the assessment at the mapped visit, the data collected at the early termination or unscheduled visit will not be included in analyses.   
In the event of multiple values from unscheduled or early termination assessment s within an 
analysis window, the value closest to the scheduled visit target study day  will be used for 
analyses.  If two values tie as closest to the time point (for example, one value is before and the 
other value is after the time point), then the later value will be selected.  
Data collected at all visits will be included in the data listings.  
7.9.3 Subject Disposition  
The number of subjects included in each analysis population (ITT and safety) , as well as the 
number of subjects in the safety population with P K data will be summarized .  The number of 
subjects treated , completed, discontinued treatment (including the reason  for treatment 
discontinuation), and discontinued study (including the primary reason for study discontinuation) will be presented . 
Subjects who are excluded from an analysis population will be summarized by the reasons for 
exclusion. 
CONFIDENTIAL  
   
Statistical Analysis Plan  for Medimetriks Pharmaceuticals, Inc.  Page 15 
Protocol Number: MEDI -MM36 -206 May 18, 2017  7.9.4 Protocol Deviations 
Protocol deviations will not be entered into the database and therefore will not be summarized.   
7.9.5 Demographic and Baseline Characteristics  
All baseline sum maries will be done on the ITT and safety populations. 
Sex, race, ethnicity, Fitzpatrick skin type, dietary habits , and alcohol, tobacco and drug use will 
be summarized by counts and percentages.  Age, h eight , and weight  will be summarized with 
descriptive statistics ( n, mean, SD , median, min , and  max ).   
Atopic dermatitis history, including family history of atopic dermatitis, location of disease , and 
diagnoses of allergic rhinitis and asthma, will be summarized by counts and percentages.  
Medi cal histories will be coded using the MedDRA dictionary and will be summarized by 
MedDRA system organ class and preferred term.  
7.9.6 Prior and Concomitant Medications  
Prior and concomitant medications will be coded to preferred term and anatomical therapeutic 
chemical (ATC) classification of ingredients using the WHO- DDE. 
Counts and percentages will be provided to summarize the use of medications other than the 
study drug reported throughout the study.  The number and percent of subjects reporting 
medications  will be summarized by  ATC level 2 term  and preferred name.  Medications which  
start prior to first dose will be considered prior medications, and medications which start on or 
after first dose will be considered concomitant medication s. Medications with inco mplete start 
dates which could be prior to first dose or after first dose will be considered concomitant. 
Skin care products used during the study and prior and concomitant procedures and therapies 
will be included in by- subject listing s. 
7.9.7 Pharmacokinetic A nalyses 
The pharmacokinetic analysis will be conducted using non- compartmental analysis on plasma 
concentrations of MM36 and its metabolites (MAP-15484, MAP15497 and MAP-15485) in the subjects in the safety population who have PK data. 
Individual plasma concentrations of MM36 and its metabolites will be summarized descriptively 
at Day 1 and Day 15 using the arithmetic mean, SD, CV%, median, min, and max. Individual 
plasma concentration -time profiles of MM36 and its metabolites will be plotted on both a line ar 
and a semi -logarithmic scale at each visit. Mean values will also be presented graphically.  
Plasma concentrations below the lower limit of quantitation  (BLQ) (< 0.2 ng/mL) will not be 
considered quantifiable concentrations. BLQ values and quantifiable concentrations will be 
CONFIDENTIAL  
   
Statistical Analysis Plan  for Medimetriks Pharmaceuticals, Inc.  Page 16 
Protocol Number: MEDI -MM36 -206 May 18, 2017  summarized separately using summary statistics. Any quantifiable concentrations at pre -dose at 
Day 1 will be set to zero in both concentration summaries, as well as in PK parameter 
calculations. Plasma concentration -time profiles will display BLQ values as 0 ng/mL on the 
linear scale, and will omit BLQ values on the semi- logarithmic scale.  
The following pharmacokinetic parameters will be analyzed for each subject at Day 1 and Day 
15 if there are a sufficient number of quantifiable concentrations of MM36 or its metabolites to 
permit their derivation.  
Cmax Maximum plasma concentration  
Cmax = BLQ if concentrations are BLQ at all time points  
Tmax Time of maximum plasma concentration  
Tmax will be calculated if at least one quantifiable plasma concentration is 
detected in the time interval. Individual elapsed sampling times will be used. If the maximum concentration is observed pre-dose, T
max will be 
considered 0 hours. 
AUC 0-last Area under the plasma concentration -time curve from time zero to the 
time of last quantifiable plasma concentration  
AUC 0-last will be calculated if at least two consecutive quantifiable 
plasma concentrations are detected in the time interval. Area will be 
computed using the linear trapezoidal rule with individual elapsed 
sampling times and observed concentratinos. BLQ values will be set to 
zero before T max and missing after T max. 
Descriptive summary statistics (n, arithmetic mean, SD, CV%, median, min, max, and  GM) will 
be reported for PK parameters. Individual plasma concentrations and PK parameter values will 
be included in by- subject listings.  
7.9.8 Efficacy Analyses 
7.9.8.1 Primary Efficacy Analysis 
There is no primary efficacy analysis.  
7.9.8.2 Secondary Efficacy Analysis 
There is no secondary efficacy analysis.  
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 7  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  7. 9. 8. 3  E x pl or at or y Effic ac y A n al yses 
 
  
 
       
 
 
 
 
  
 
 
 
  
 
  
 
  
 
  
 
 
 
 
 
 
 
  C or p or at e C o nfi d e nti al I nf or m ati o n 
 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 8  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7   
 
  
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
  
 
 
 
 
 
  
  
 
  
  
  
 C or p or at e C o nfi d e nti al I nf or m ati o n 
 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 1 9  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  7. 9. 8. 3. 4. 2   
 
 
  
 
 
  
  
  
 
 
  
 
 
 
 
  
  
 
 
  
 
 
 
 
 
 
 
 
 
 C or p or at e C o nfi d e nti al I nf or m ati o n 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 2 0  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7   
 
  
  
 
  
 
 
  
  
 
7. 9. 9  S af et y A n al yses 
7. 9. 9. 1  E xte nt of E x p os ure 
T he e xte nt of e x p os ure t o st u d y dr u g will be s u m m arize d b y t otal n u m ber of da ys of e x p os ure, 
t otal n u m ber of a p plicati o ns, perce nt c o m plia nce , a n d t otal a m o u nt of st u d y dr u g a p plie d. T otal 
n u m ber of a p plicati o ns will be deter mi ne d b y t he n u m ber of e ntries i n t he d osi n g diar y. T otal 
n u m ber of da ys of e x p os ure will be c o m p ute d as f oll o ws: 
Da ys of E x p os ure = D ate of Last Ap plicati o n  – Date of First A p plicati o n + 1. 
T o c o m p ute per ce nt c o m plia nce, t otal n u m ber of e x pecte d a p plicati o ns will be calc ulate d b y:  
E x pecte d a p plicati o ns = 2 *( St u d y C o m pleti o n/ Disc o nti n uati o n Date  – Dat e of First A p plicati o n).  
If t he t otal n u m ber of e x pecte d a p plicati o ns e x cee ds 5 8 t he n it will be set t o 5 8. Perce nt 
c o m plia nce will be calc ulate d fr o m t otal n u m ber of a p plicati o ns a n d t otal n u m ber of e x pecte d 
a p plicati o ns as f oll o ws: 
Perce nt C o m plia nce  = 1 0 0 *( T otal A p plicati o ns/ E x pecte d A p plicati o ns). 
Perce nt c o m plia nce will n ot be calc ulate d f or s u bj ects w h o ar e l ost t o f oll o w- u p. 
7. 9. 9. 2  A d verse E ve nts  C or p or at e C o nfi d e nti al I nf or m ati o n 
Treat me nt -e mer ge nt A Es ( T E A Es) are defi ne d as A Es wit h a n o nset o n or after t he d ate of t he 
first st u d y dr u g  a p plicati o n. Treat me nt -e mer ge nt A Es will be s u m marize d b y s yste m  or ga n class 
a n d pref err e d ter m  a n d f urt her b y se verit y a n d rel ati o ns hi p t o st u d y dr u g. W he n s u m marizi n g 
A Es b y s e verit y a n d relati o ns hi p, eac h s u bject will be c o u nte d o nce w it hi n a s yste m or ga n class 
CONFIDENTIAL  
   
Statistical Analysis Plan  for Medimetriks Pharmaceuticals, Inc.  Page 21 
Protocol Number: MEDI -MM36 -206 May 18, 2017  or preferred term by using the event  with the highest severity and strongest relation ship within 
each classification.  
Serious AEs (SAEs) will be summarized by system organ class, preferred term, severity , and 
relationship to stu dy drug. Application site AEs and any TEAEs reported by ≥ 5% of subjects 
will be summarized by system organ class and preferred term. Adverse events leading to 
treatment or study discontinuation will be summarized by system organ class and preferred term.  
Listings will be presented for all adverse events as well as for serious adverse events, and 
adverse events leading to discontinuation from the study. 
7.9.9.3 Clinical Laboratory Evalutions 
Laboratory test results will be summarized with descriptive statistics at Baseline and Day 29 . 
Additionally, change from baseline values will be summarized at Day 29, and shifts from 
Baseline to Day 29 in laboratory test results based on normal ranges will be summarized with 
frequency counts and percentages . Individual laborator y test results , including urine and serum 
pregnancy test results, will be presented in a by -subject listing.   
7.9.9.4 Other Observations Related to Safety  
7.9.9.4.1 ECG Measurements  
ECGs will be performed in triplicate at Screening, Day 1, Day 15 and Day 29, and the followi ng 
parameters will be measured for each ECG: heart rate, RR duration, QRS duration, PR duration, 
QT duration, QT interval corrected for heart rate using Bazett’s formula  (QTcB ), and QT interval 
corrected for heart rate using Fridericia’s formula  (QTcF ). For each parameter  and each visit, the 
mean of all measurements collected at the visit will be calculated, so each subject will have one 
value associated with each ECG parameter at each visit.  
Descriptive statistics at Baseline, Day 15 , and Day 29 will be provided for each ECG parameter. 
Change from baseline values will be summarized at Day 15 and Day 29. 
Individual ECG measurements, as well as means of triplicates, will be presented in a by -subject 
listing.  
7.9.9.4.2 Vital Signs  
Temperature, respiratory rate, heart rate, blood pressure, and weight will be summarized at each 
visit, and change from baseline values will be presented for post-b aseline visits. Weight will be 
summarized at Baseline, Day 15 , and Day 29, and all other vital signs will be summarized at 
Baseli ne, Day 8, Day 15, Day 22, and Day 29. 
Heart rate and blood pressure measurements are collected in triplicate at each visit. Prior to 
computing summary statistics, the mean of each measurement will be calculated for each subject 
C O N FI D E N TI A L  
   
Statistical A nal ysis Pla n  f or Me di metri ks P har mace uticals, I nc.  P a ge 2 2  
Pr ot oc ol N u m ber: M E DI -M M 3 6 -2 0 6  Ma y 1 8, 2 0 1 7  at eac h visit. S u m mar y stat istics will be c o m p ute d fr o m eac h s u bject’s mea n heart r ate a n d bl o o d 
press ure v al ues at eac h visit.  
I n di vi d ual vital si g n data, as well as mea ns of heart rate a n d bl o o d pr ess ure tri plicates, will be 
prese nte d i n a b y -s u bject listi n g.  
7. 9. 9. 4. 3  P h ysic al E x a mi n ati o n 
P h ysical e x a mi nati o n data will be prese nt e d i n a b y -s u bject listi n g.  
8.  RE F E R E N C E S  
 
 
 C or p or at e C o nfi d e nti al I nf or m ati o n 
 